CA2310534A1 - Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) - Google Patents

Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) Download PDF

Info

Publication number
CA2310534A1
CA2310534A1 CA002310534A CA2310534A CA2310534A1 CA 2310534 A1 CA2310534 A1 CA 2310534A1 CA 002310534 A CA002310534 A CA 002310534A CA 2310534 A CA2310534 A CA 2310534A CA 2310534 A1 CA2310534 A1 CA 2310534A1
Authority
CA
Canada
Prior art keywords
agent
tumor
nervous system
central nervous
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002310534A
Other languages
French (fr)
Other versions
CA2310534C (en
Inventor
Ruediger Stendel
Rolf W. Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27538049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2310534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Publication of CA2310534A1 publication Critical patent/CA2310534A1/en
Application granted granted Critical
Publication of CA2310534C publication Critical patent/CA2310534C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system.
Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.

Claims (19)

1. A method of treating tumors of the central nervous system (CNS) in a mammal comprising administering an effective dose of a CNS tumor-inhibiting methylol transfer agent to a mammalian subject at risk of central nervous system tumor growth.
2. A method of claim 1, wherein said agent is Taurolidine, Taurultam or a mixture thereof.
3. A method as claimed in claim 1 wherein said agent is administered by injection or infusion.
4. A method as claimed in claim 1 wherein said agent is administered locally by a probe using microdialysis.
5. A method as claimed in claim 4 wherein said probe is placed using neuronavigation, MRI guidance, or ultrasound-guidance.
6. A method as claimed in claim 4 wherein a diagnostic biopsy is taken from the tumor during a same procedure as administration of said agent.
7. A method as claimed in claim 4 wherein fluid is obtained from a region of said tumor by said probe.
8. A method as claimed in claim 1 wherein said agent is administered locally by an implanted catheter.
9. A method as claimed in claim 1 wherein said agent is administered locally using irrogation of a region of an extirpated tumor.
10. A method as claimed in claim 1 wherein said agent is administered intravenously in a dose range of about 50 - 500 mg/kg per day.
11. A method as claimed in claim 1 wherein said agent is administered locally by administration of an isotonic solution of said agent.
12. A method claimed in claim 1 wherein said tumor is selected from gliomas, glioblastomas, astrocytomas, ependymomas, plexus carcinomas, plexus papillomas, medulloblastomas, neuroblastomas, gangliogliomas, gangliogliomas, ganglioneuromas, pineoblastomas, malignant menigeomas, gliomatosis cerebri, teratomas of the pineal gland, retinoblastomas and mixed-cell-tumors.
13. A method as claimed in claim 1 comprising further administering to said mammal a cytotoxic antineoplastic agent, an alkylating agent, or a tumor metabolism agent.
14. A method as claimed in claim 1 comprising further administration of interleukin-1, interleukin-2, or interferon.
15. A method as claimed in claim 1 further comprising administering said agent in a matrix applied into a tumor cavity of said mammal.
16. The method of claim 1 wherein said agent is Taurultam-glucose.
17. A pharmaceutical composition comprising a methylol transfer agent and at least one antineoplastic agent, immunomodulating agent or central nervous system tumor metabolism agent for administration to a mammal at risk of central nervous system tumor growth.
18. The composition of claim 17, wherein said agent is Taurolidine, Taurultam or a mixture thereof.
19. The composition of claim 17, wherein said agent is Taurultam-glucose.
CA2310534A 1999-06-04 2000-06-02 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) Expired - Fee Related CA2310534C (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13742199P 1999-06-04 1999-06-04
US60/137,421 1999-06-04
US15105099P 1999-08-27 1999-08-27
US60/151,050 1999-08-27
US16768199P 1999-11-29 1999-11-29
US60/167,681 1999-11-29
US17460700P 2000-01-05 2000-01-05
US60/174,607 2000-01-05
US18220000P 2000-02-14 2000-02-14
US60/182,200 2000-02-14

Publications (2)

Publication Number Publication Date
CA2310534A1 true CA2310534A1 (en) 2000-12-04
CA2310534C CA2310534C (en) 2011-01-18

Family

ID=27538049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2310534A Expired - Fee Related CA2310534C (en) 1999-06-04 2000-06-02 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns)

Country Status (7)

Country Link
US (4) US6479481B1 (en)
EP (2) EP1595543B1 (en)
JP (2) JP2001010976A (en)
AT (1) ATE311179T1 (en)
CA (1) CA2310534C (en)
DE (1) DE60024360T2 (en)
ES (2) ES2251939T3 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20020098164A1 (en) 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
EP1248625A2 (en) 1999-12-06 2002-10-16 Rhode Island Hospital Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
CN100519525C (en) * 1999-12-06 2009-07-29 葛兰素集团有限公司 Aromatic sulfones and their medical use
EP1797884B1 (en) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
CA2441016A1 (en) * 2001-03-15 2002-09-26 Paul Calabresi Taurine compounds
CA2462564C (en) 2001-10-01 2012-07-10 Rhode Island Hospital Methods of inhibiting metastases
JP2003119136A (en) * 2001-10-10 2003-04-23 Mutsuyuki Kochi Differentiation inducing agent composition for malignant cell and use thereof
AU2004201264B2 (en) * 2003-03-28 2009-12-24 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Adhesive Antineoplastic Compositions
CA2482687C (en) 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
WO2007019065A2 (en) * 2005-08-04 2007-02-15 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
EP2061429A2 (en) * 2006-09-07 2009-05-27 Ed. Geistlich Söhne Ag Für Chemische Industrie Method of treating bone cancer
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381060A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CN108778339A (en) * 2016-01-11 2018-11-09 科医公司 Therapeutic nano particle for treating neuroblastoma and other cancers
CN105943522B (en) * 2016-05-19 2019-06-21 中国医学科学院基础医学研究所 Clofoctol is used to prepare the purposes of the drug for the treatment of human glioma
KR101880015B1 (en) * 2017-12-08 2018-07-19 아주대학교산학협력단 Composition comprising Interferon-gamma for preventing or treating of neurofibrosarcoma
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328111D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
JP3580867B2 (en) * 1994-09-07 2004-10-27 株式会社東芝 Medical sonde
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
JP2001525703A (en) * 1997-05-15 2001-12-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Method and apparatus for targeted dosing of patients using magnetic resonance imaging
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
EP1248625A2 (en) * 1999-12-06 2002-10-16 Rhode Island Hospital Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Also Published As

Publication number Publication date
EP1595543A2 (en) 2005-11-16
JP2001010976A (en) 2001-01-16
DE60024360T2 (en) 2006-06-08
EP1066830A2 (en) 2001-01-10
ES2251939T3 (en) 2006-05-16
EP1595543A3 (en) 2006-08-02
ATE311179T1 (en) 2005-12-15
US6815441B2 (en) 2004-11-09
US6479481B1 (en) 2002-11-12
CA2310534C (en) 2011-01-18
EP1066830B1 (en) 2005-11-30
ES2532259T3 (en) 2015-03-25
JP2008195726A (en) 2008-08-28
DE60024360D1 (en) 2006-01-05
EP1595543B1 (en) 2014-12-17
US20030064942A1 (en) 2003-04-03
US20030195198A1 (en) 2003-10-16
EP1066830A3 (en) 2002-10-16
US20100048542A1 (en) 2010-02-25
US7638511B2 (en) 2009-12-29
US8202860B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
CA2310534A1 (en) Methods and compositions for treating primary and secondary tumors of the central nervous system (cns)
EP0723444B1 (en) Levobupivacaine useful for managing chronic pain
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
JP2001010976A5 (en)
CA2405796A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
JP2006213736A (en) Analgesic agent and use thereof
Sanders 3, 4‐Diaminopyridine (DAP) in the Treatment of Lambert‐Eaton Myasthenic Syndrome (LEMS) a
KR950703949A (en) Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds
CA2122596C (en) Treatment of neurological conditions by an interleukin-1 inhibiting compound
EP0563127B1 (en) Improved treatment method for cancer
JPS61212520A (en) Blend and method for alleviating long term pain
IL128613A (en) Dual non-selective beta-adrenoreceptor and alpha1-adrenoreceptor antagonist for inhibiting the expression of fas
AU607941B2 (en) Active compounds for preventing tumor metastases
JPS61155324A (en) Anticancer drug and remedy
US6841576B2 (en) Anti-hypertensive composition and methods of treatment
US10507228B2 (en) Methods and compositions related to KRAS inhibitors
Frank et al. Stereotactic mesencephalotomy versus multiple thalamotomies in the treatment of chronic cancer pain syndromes
KR100508623B1 (en) New use of a macrolide compound
SK10596A3 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
KR100699737B1 (en) Remedies for nervous diseases
Cervellino et al. Combined hormonal therapy with high‐dose diethylstilbestrol diphosphate (DES‐DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: A controlled study
CA1298549C (en) COMPOSITIONS CONTAINING GOLGI .alpha.-MANNOSIDASE II INHIBITORS
WO2001000240A2 (en) Antitumor compound
MXPA99008056A (en) The use of levobupivacaine or ropivacaine in treating migraine
RU97113692A (en) APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CEREBRAL DEGENERATIVE DISORDERS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190603